TRAX Stock News & Catalysts – First Tracks Biotherapeutics

FEATURED

First Tracks Biotherapeutics Announces Participation in Upcoming Investor Conferences

SAN DIEGO, Nov. 03, 2026 (GLOBE NEWSWIRE) -- First Tracks Biotherapeutics, Inc. (NASDAQ:TRAX), a clinical stage biotechnology company advancing antibody therapeutics that modulate immune pathways implicated in

Summary

Nov 3, 2026, 4:15 PM ·Globe Newswire

RECENT

First Tracks Biotherapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update

Announced ANB033 achieved a statistically significant and clinically meaningful protective effect on both gluten-induced intestinal damage and symptoms in Cohort 1 (gluten challenge) of Phase 1b trial in celiac disease

Nov 3, 2026, 4:15 PM ·Globe Newswire

First Tracks Biotherapeutics Announces $200 Million Private Placement

SAN DIEGO, Oct. 15, 2026 (GLOBE NEWSWIRE) -- First Tracks Biotherapeutics, Inc. (NASDAQ:TRAX), a clinical stage biotechnology company advancing antibody therapeutics that modulate immune pathways implicated in

Oct 15, 2026, 8:00 AM ·Globe Newswire

First Tracks Biotherapeutics Announces Positive Top-Line Results for ANB033 in Gluten-Challenge Study in Celiac Disease

ANB033 achieved a statistically significant and clinically meaningful protective effect on both gluten-induced intestinal damage and symptomsLS mean change from baseline in Vh:Cd ratio of -0.17 on ANB033 vs. -0.66 on

Oct 12, 2026, 7:00 AM ·Globe Newswire

First Tracks Biotherapeutics to Announce Top-Line Data from Cohort 1 of Phase 1b Trial of ANB033, a CD122 antagonist, in Celiac Disease on Oct. 12, 2026

SAN DIEGO, Oct. 11, 2026 (GLOBE NEWSWIRE) -- First Tracks Biotherapeutics, Inc. (NASDAQ:TRAX), a clinical-stage biotechnology company advancing antibody therapeutics that modulate immune pathways implicated in

Oct 11, 2026, 4:00 PM ·Globe Newswire

First Tracks Biotherapeutics Announces Participation in September Investor Conferences

SAN DIEGO, Aug. 26, 2026 (GLOBE NEWSWIRE) -- First Tracks Biotherapeutics, Inc. (NASDAQ:TRAX), a clinical-stage biotechnology company advancing antibody therapeutics that modulate immune pathways implicated in

Aug 26, 2026, 4:15 PM ·Globe Newswire

First Tracks Biotherapeutics Announces Second Quarter 2026 Financial Results and Provides Business Update

Completed enrollment for Cohort 1 (gluten challenge) of Phase 1b ANB033 trial in celiac disease (CeD); top-line Cohort 1 data reaffirmed for Q4 2026Cohort 2 (mucosal healing) enhanced to enroll up to 40 patients

Aug 12, 2026, 4:15 PM ·Globe Newswire

First Tracks Biotherapeutics Announces Participation in Upcoming Investor Conferences

SAN DIEGO, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- First Tracks Biotherapeutics, Inc. (NASDAQ:TRAX), a clinical-stage biotechnology company advancing antibody therapeutics that modulate immune pathways implicated in

May 21, 2026, 4:15 PM ·Globe Newswire

First Tracks Biotherapeutics Announces First Quarter 2026 Financial Results and Provides Business Update

First Tracks launched April 20th with a two-year cash-runway to advance ANB033 through celiac disease and eosinophilic esophagitis Phase 1b data and plans to initiate Phase 2 trials across four indications SAN DIEGO,

May 14, 2026, 4:15 PM ·Globe Newswire

First Tracks Biotherapeutics Debuts on Nasdaq to Advance Therapies for Autoimmune Diseases

First Tracks Biotherapeutics launches with $180 million in cash and two-year cash-runwayTrading of TRAX begins on Nasdaq today SAN DIEGO, April 20, 2026 (GLOBE NEWSWIRE) -- First Tracks Biotherapeutics, Inc.

Apr 20, 2026, 9:15 AM ·Globe Newswire

Anaptys Announces $100 Million Stock Repurchase Plan and Provides a Business Update

Anaptys to spin-off biopharma operations into First Tracks Biotherapeutics, with a target distribution date of April 20, 2026Anaptys to manage the financial collaborations for Jemperli with GSK and imsidolimab with

Mar 27, 2026, 9:00 AM ·Globe Newswire

Anaptys Provides Update on Business Separation and Announces Fourth Quarter and Full Year 2025 Financial Results

Spin-off of biopharma operations into a public company to be called "First Tracks Biotherapeutics" on track for Q2 2026, potentially as early as late-AprilPhase 1b enrollment ongoing in celiac disease and trial cohort

Mar 3, 2026, 4:15 PM ·Globe Newswire

First Tracks Biotherapeutics Inc TRAX · News